Zhimeng Biopharma Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Latest Deal Type
  • Early Stage VC
  • Latest Deal Amount
  • $14.2M
Latest Deal Amount
  • Investors
  • 3

Zhimeng Biopharma General Information

Description

Developer of pharmaceuticals designed to target all stages of the hepatitis B virus. The company has nuclecapsid inhibitor, RNA destabilizer and immunomodulator projects in the pipeline, enabling healthcare professionals to prescribe better treatments to patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • Room 5-N
  • No. 780 Cailun Road, Pudong New Area
  • Shanghai, 201203
  • China
+86 021 0000 0000

Zhimeng Biopharma Timeline

2017201820192020
Financing RoundFinancing Round
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Zhimeng Biopharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC 11-Nov-2019 $14.2M 000.00 Completed Clinical Trials - Phase 1
1. Early Stage VC 05-Feb-2018 Completed Startup
To view Zhimeng Biopharma’s complete valuation and funding history, request access »

Zhimeng Biopharma Executive Team (2)

Name Title Board Seat Contact Info
Huanming Chen Ph.D Chief Executive Officer & Founder
Zhijun Zhang Co- Founder, Chief Scientific Officer & Vice President
To view Zhimeng Biopharma’s complete executive team members history, request access »

Zhimeng Biopharma Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Shenzhen Capital Group Venture Capital Minority 000 0000 000000 0
BOHE Angel Fund Venture Capital Minority 000 0000 000000 0
Legend Star Corporate Venture Capital Minority 000 0000 000000 0
To view Zhimeng Biopharma’s complete investors history, request access »